Drug Res (Stuttg) 2013; 63(S 01): S8
DOI: 10.1055/s-0033-1346708
Symposium der Paul-Martini-Stiftung
Georg Thieme Verlag KG Stuttgart · New York

The Role of GM-CSF in Multiple Sclerosis

A. Schottelius
Chief Development Officer, MorphoSys AG, Martinsried
› Author Affiliations
Further Information

Publication History

Publication Date:
15 November 2013 (online)

Multiple sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system, which is characterized pathologically by demyelination and subsequent axonal degeneration. Infiltrating macrophages have been identified to contribute significantly to demyelination in both clinical MS and animal models of MS. GM-CSF stimulates proliferation and activation of macrophages, monocytes, neutrophils, eosinophils, dendritic cells and microglia with subsequent induction of pro-inflammatory biomolecules. GM-CSF might therefore be involved in the inflammatory processes related to MS. Elevated concentrations of GM-CSF have been shown in the cerebrospinal fluid but not in the serum of patients suffering from relapsing-remitting or secondary progressive MS [1], [2]. Similarly, GM-CSF levels were reported to be higher in the cerebrospinal fluid, but not in the serum of patients with active phase of relapsing-remitting MS and in patients with remission in comparison to control patients suffering from other non-inflammatory neurological diseases [3].

  • References

  • 1 Perella et al.. . Eur Neurol 1993; 33: 152-155
  • 2 Mellegård et al.. . Mult Scler 2010; 16: 208-217
  • 3 Carrieri et al.. . Immunopharmacol Immunotoxicol 1998; 20: 373-382
  • 4 McQualter et al.. . J Exp Med 2001; 194: 873-881
  • 5 Ponomarev et al.. . J Immunol 2007; 178: 39-48
  • 6 Codarri et al.. . Nature Immunol 2011; advance online publication
  • 7 El-Behi et al.. . Nature Immunol 2011; advance online publication
  • 8 King et al.. . Blood 2009; 113: 3190-3197